BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30709339)

  • 1. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
    Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
    Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
    Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
    Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
    Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
    Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
    Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
    J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
    Xu JX; Yang Y; Zhang X; Luan XP
    Anat Rec (Hoboken); 2021 Feb; 304(2):342-352. PubMed ID: 32275350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
    Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
    Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells.
    Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ
    Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
    Shang C; Tang W; Pan C; Hu X; Hong Y
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
    Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
    J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
    Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
    Front Immunol; 2021; 12():802795. PubMed ID: 35069587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
    Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
    ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.